Precipio, Inc. (PRPO)

NASDAQ: PRPO · IEX Real-Time Price · USD
6.41
-0.07 (-1.12%)
Feb 26, 2024, 4:00 PM EST - Market closed
-1.12%
Market Cap 9.10M
Revenue (ttm) 13.26M
Net Income (ttm) -9.07M
Shares Out 1.42M
EPS (ttm) -7.44
PE Ratio n/a
Forward PE 15.92
Dividend n/a
Ex-Dividend Date n/a
Volume 1,159
Open 6.21
Previous Close 6.48
Day's Range 6.24 - 6.41
52-Week Range 4.75 - 17.20
Beta 1.60
Analysts n/a
Price Target n/a
Earnings Date Apr 1, 2024

About PRPO

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut. [Read more]

Sector Healthcare
CEO Ilan Danieli
Employees 53
Stock Exchange NASDAQ
Ticker Symbol PRPO
Full Company Profile

Financial Performance

In 2022, Precipio's revenue was $9.41 million, an increase of 6.36% compared to the previous year's $8.85 million. Losses were -$12.20 million, 43.1% more than in 2021.

Financial Statements

News

Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY

NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for the full year of 2023, its unaudited revenues have grown fro...

13 days ago - GlobeNewsWire

Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for i...

20 days ago - GlobeNewsWire

Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter

Results clearly demonstrate the business's ability to reach breakeven in the near future Results clearly demonstrate the business's ability to reach breakeven in the near future

4 weeks ago - GlobeNewsWire

Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan

NEW HAVEN, Conn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into an agreement with a Japanese distributor for the sa...

5 weeks ago - GlobeNewsWire

Precipio Announces Christina Valauri joins the Board of Directors

Douglas Fisher, MD will step down as Director, and remain as a board observer Douglas Fisher, MD will step down as Director, and remain as a board observer

7 weeks ago - GlobeNewsWire

Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024

NEW HAVEN, Conn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc.  ( NASDAQ: PRPO) shares thoughts and reflections looking back at 2023, and forwar...

2 months ago - GlobeNewsWire

Precipio Announces Q3-2023 Shareholder Update Call

NEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2023 corporate update call on November 20th, 2023 at 5:00...

3 months ago - GlobeNewsWire

Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022

NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3...

4 months ago - GlobeNewsWire

Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023

Company anticipates current cash levels sufficient to reach breakeven Company anticipates current cash levels sufficient to reach breakeven

5 months ago - GlobeNewsWire

Precipio Continues to Sign New HemeScreen™ Customers

NEW HAVEN, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) announced that new customer orders are expected to bring total Q4 HemeScreen ...

5 months ago - GlobeNewsWire

Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven

Higher pathology revenues and lower cost structure drive down product revenue breakeven point from $8M to $6M Higher pathology revenues and lower cost structure drive down product revenue breakeven po...

5 months ago - GlobeNewsWire

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

NEW HAVEN, Conn., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO) today announced that it has implemented a 1-for-20 reverse stock split of outs...

5 months ago - GlobeNewsWire

Precipio's Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan

NEW HAVEN, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces its Pathology Division has in August exceeded the monthly breakeven ...

5 months ago - GlobeNewsWire

Precipio Announces Q2-2023 Shareholder Update Call

NEW HAVEN, Conn., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2023 corporate update call on August 17th at 5:00 PM ET.

7 months ago - GlobeNewsWire

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces the launch of its new quantitative BCR-ABL 2.0 panel, with features m...

7 months ago - GlobeNewsWire

Precipio's Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven

These efficiencies plus revenue growth expected to continue the positive momentum These efficiencies plus revenue growth expected to continue the positive momentum

7 months ago - GlobeNewsWire

Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023

Revenue growth and customer pipeline advance the Company towards breakeven Revenue growth and customer pipeline advance the Company towards breakeven

7 months ago - GlobeNewsWire

Precipio's Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy

Use of HemeScreen® technology enables diagnosis without the need for painful, invasive sampling Use of HemeScreen® technology enables diagnosis without the need for painful, invasive sampling

9 months ago - GlobeNewsWire

Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

New panel will enable rapid, precise genetic profiling of patients with deadly disease New panel will enable rapid, precise genetic profiling of patients with deadly disease

9 months ago - GlobeNewsWire

Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) , today announced it has entered into securities purchase agreements with cert...

9 months ago - GlobeNewsWire

Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects

Independent of revenue growth, these Projects expected to decrease cash burn by 25% in Q3 Independent of revenue growth, these Projects expected to decrease cash burn by 25% in Q3

9 months ago - GlobeNewsWire

Precipio's Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

Panel-Based Approach of Driver Mutation Detection Proves Crucial for Patient Care Panel-Based Approach of Driver Mutation Detection Proves Crucial for Patient Care

10 months ago - GlobeNewsWire

Precipio Shares Growth Catalysts For HemeScreen

NEW HAVEN, Conn., May 17, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) , will be discussing on today's shareholders call several growth catalysts that...

10 months ago - GlobeNewsWire

Precipio Announces Q1-2023 Shareholder Update Call

NEW HAVEN, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2023 corporate update call on May 17th at 5:00 PM ET.

10 months ago - GlobeNewsWire

Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

Customer's pathology services annual revenues expected to exceed $1.5M Customer's pathology services annual revenues expected to exceed $1.5M

10 months ago - GlobeNewsWire